tbuckley/cabot-search huggingface dataset:
Abstract 9581: Bendavia, a Novel Mitochondrial-Targeted Cytoprotective Compound Reduces Ischemia/Reperfusion Injury: Experience in 3 Independent Laboratories
Authors: Robert A Kloner, Sharon L Hale, Robert C Gorman, Takashi Shuto, Kevin J Koomalsingh, Joseph H Gorman, Ruben C Sloan, Chad R Frasier, Alan P Kypson, David A Brown
Journal: Circulation (2011)

Bendavia is a mitochondrial-targeting compound proposed to maintain cardiac mitochondrial function and decrease permeability transition pore (PTP) opening during ischemia/reperfusion (IR). Our labs assessed the cardioprotective effects of Bendavia using cellular and large animal models of IR when reactive oxygen species (ROS) generation is elevated. Left ventricular guinea pig cardiomyocytes were either untreated or incubated with 1nM Bendavia and exposed to 20 min of cellular anoxia plus 30 min of reoxygenation in a hypoxia chamber. Following reoxygenation 54% of control cells survived to the end of reoxygenation versus 93% of Bendavia-treated cells (p&lt;0.05). Myocytes displayed bursts in ROS production immediately prior to cell death that were prevented by Bendavia. Similarly, Bendavia maintained mitochondrial membrane potential in cells exposed to oxidative challenge, suggesting that scavenging mitochondrial ROS with Bendavia sustained mitochondrial energetics by keeping PTP closed. A second study determined the effect of Bendavia on infarct size in anesthetized sheep (60 min coronary occlusion, 3 hr reperfusion). Bendavia infusions of 0.005, 0.05 and 0.5 mg/kg/hr were administered 30 min after occlusion and reduced mean infarct size by 25%, 16% and 17%, respectively (p≤0.05 versus vehicle). Cyclosporin A reduced infarct size by &lt;10% in this same study (p=NS). In a third study anesthetized rabbits received 30 min of coronary artery occlusion plus 3 hr of reperfusion. Rabbits received placebo or Bendavia at 10 or 20 min after occlusion or immediately before reperfusion. At 3 hr of reperfusion, no reflow was assessed by Thioflavin S injection. For any size of ischemic risk zone, the no reflow zone was significantly smaller in the Bendavia group than control group (p=0.0085). There was an overall 21% reduction in no reflow and 11% reduction in infarct size in the Bendavia group. Cardiac hemodynamics were not influenced by Bendavia or Cyclosporin A in either the sheep or rabbit studies. In 3 separate labs studying IR injury, Bendavia protected cardiomyocytes along with reducing infarct size and limiting no reflow when given after ischemia, but prior to reperfusion, making the compound an attractive candidate for clinical studies in cardiac IR injury.
Aortic Dissection
Authors: Amritpal Singh Nat, Dinesh Subedi
Journal: New England Journal of Medicine (2014)

An 81-year-old man presented with suprapubic pain and urinary retention. Echocardiography showed aneurysmal dilatation and a dissection flap in the ascending aorta, shown in a short video. CT angiography revealed an ascending aortic aneurysm and a type I DeBakey aortic dissection.
Gait patterns of depressed patients and normal subjects
Authors: L Sloman, M Berridge, S Homatidis, D Hunter, T Duck
Journal: American Journal of Psychiatry (1982)

The authors compared the gait patterns of 15 patients with affective disorders with those of 15 normal control subjects. The procedure involved a frame-by-frame analysis of a film of each subject walking at normal speed. Angle measurements were made of the hip and knee at their maximum extension during a single gait cycle (one stride). The results generally support the hypothesis that depressed patients walk with a lifting motion of the leg, whereas normal control subjects propel themselves forward.
Prognostic factors in HIV-related diffuse large cell lymphoma (HIV-DLCL) in the pre and post-HAART (HT) era
Authors: S. T. Lim, R. Karim, A. Tulpule, B. N. Nathwani, A. M. Levine
Journal: Journal of Clinical Oncology (2005)

6523 Background: Prognosis of patients (pts) with HIV-NHL has improved in the post-HT era. We compared factors predictive of survival in pre vs post-HT eras among pts with HIV-DLCL. Methods: 228 pts with HIV-DLCL were included; pathology was reviewed by an expert hematopathologist (BNN). Pre-HT included pts diagnosed before 1997, who did not receive HT; post-HT included pts diagnosed after 1997, who received HAART. Results: There were no statistically significant differences in the HIV or lymphoma-related characteristics between the two periods, although a trend towards higher median CD4 count in post-HT era was seen (94 vs. 62/mm3 p=0.07). CHOP or mBACOD- based chemotherapy was used in the majority of both groups (75% vs. 84%, p=0.12). In treated pts, the complete remission (CR) rate has improved from 33% in pre-HT to 56% in the post-HT period (p=0.0004), while the median survival (OS) has improved from 8.3 to 43.2 months (p=0.0005). Univariate data shown in table below. On multivariate analyses, in the pre-HT period, factors associated with decreased survival included (1) a KPS<80 [Hazard ratio (HR): 2.2, 95% CI, 1.5–3.5, p=0.0003) and (2) no attainment of CR (HR: 3.3, 95% CI 2.0–5.5, P<0.0001). In contrast, factors independently associated with short survival in the post-HT era included (1) elevated LDH (HR: 2.5, 95% CI, 1.0–6.1, P=0.05), (2) high risk IPI (HR: 2.1, 95%CI,1.7–15.4, P=0.004), (3) no attainment of CR (HR: 11.6, 95%CI,4.2–32.3, P<0.0001) and (4) a history of prior AIDS (HR: 3.3, 95%CI,1.4–7.6, P=0,05). Conclusions: 1) CR and OS have significantly improved among pts with HIV-DLCL in the post-HT era, along with increase in median CD4. (2) Factors associated with poor survival in post-HT are now similar to those seen in HIV negative patients, including high LDH, high risk IPI, and no attainment of CR, in addition to history of AIDS Author Disclosure Patient Characteristics and Prognostic Factors: Pre and Post-HT Characteristics Pre-HAART N=145(%) Post-HAART N=83(%) P value Pre-HT: Univariate analysis P value Post-HT: Univariate analysis P value Male vs. Female 94 vs. 6% 94 vs. 6% 0.9 0.09 0.56 CD 4<100 vs. >100 63 vs. 37% 46 vs. 54% 0.33 0.007 0.14 Prior AIDS yes vs. no 44 vs. 56% 33 vs. 67% 0.15 0.003 0.001 Stage III/IV vs. I/II 73 vs. 27% 78 vs. 22% 0.4 0.81 0.12 KPS<80 vs. >80 45 vs. 55% 36 vs. 64% 0.19 0.0001 <0.0001 LDH high vs. normal 66 vs. 34% 64 vs. 36% 0.7 0.09 0.09 CR no vs. yes 68 vs. 32% 44 vs. 56% 0.0004 <0.0001 0.0001 IPI 1 2 3 (Age adjusted) 31% 34% 24% 28% 32% 24% NS 0.02 0.56 0.002 0.06 0.19 <0.001 No significant financial relationships to disclose.
The Value of Scholarship
Authors: Chas. Gordon Heyd
Journal: Annals of Internal Medicine (1927)

Article1 October 1927The Value of ScholarshipCHAS. GORDON HEYD, B.A., M.D., F.A.C.SCHAS. GORDON HEYD, B.A., M.D., F.A.C.SSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-1-4-251 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptSixteen years ago I graduated in medicine and am returning tonight to acknowledge my great obligation to the Medical Department of the University of Buffalo.You may remember that when Dante and his companion had climbed, with considerable toil, up the Mountain of Purgatory they approached a wide and pleasant looking terrace encircling the hill and being tired they sat down to rest and Dante, looking back upon the steep ascent to the terrace upon which they rested, turned to his conductor and said, "All men like to look backward."If one could dispassionately examine the period of preparation and... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York Post-Graduate Medical School and Hospital*Delivered before the Epsilon Chapter of Alpha Omega Alpha Fraternity, Buffalo, New York. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1927Volume 1, Issue 4Page: 251-255 Issue Published: 1 October 1927 PDF DownloadLoading ...
Abstract 15333: Aging Signs Predict Risk of Ischemic Vascular Disease Independent of Chronological Age
Authors: Mette Christoffersen, Ruth Frikke-Schmidt, Peter Schnohr, Gorm B Jensen, Borge G Nordestgaard, Anne Tybjaerg-Hansen
Journal: Circulation (2012)

INTRODUCTION: The physical examination of a patient often includes an assessment of whether a patient looks older than his or her actual age. This practice assumes that patients appearing older tha...
Abstract 18940: Application of the HeartMateII Risk Score in Patients With Continuous Flow Left Ventricular Assist Devices
Authors: Sunu S Thomas, Nadav Nahumi, Jason Han, Matthew Lippel, Melana Yuzefpolskaya, Paolo Colombo, Hiroo Takayama, Yoshifumi Naka, Nir Uriel, Ulrich P Jorde
Journal: Circulation (2013)

Background: Survival with left ventricular assist device (LVAD) therapy is dependent on appropriate patient selection. The Heart Mate II Risk Score (HMRS) was recently derived and validated in clinical trial patients to predict 90 day mortality following implantation of a continuous flow LVAD. The aim of this study was to test the validity of the HMRS in our patient population. Methods: We performed a retrospective analysis of patients implanted with HeartMate II (Thoratec, Pleasanton, CA) LVADs from March 31, 2004 to September 20, 2012. Patients were stratified according to HMRS profiles (HMRS Low &lt; 1.58; &lt; 1.58 HMRS Medium &lt; 2.48; HMRS High &gt; 2.48) calculated using age, albumin, creatinine, international normalized ratio (INR) and center volume. Outcome was defined as survival at 90 days post-device implantation. Results: HeartMate II LVADs were implanted in 205 patients. Pre-operative data from 201 patients were categorized into HMRS Low (n=101; 1.04 (0.64-1.31)), HMRS Medium (n=73; 1.98 (1.78-2.25)), and HMRS High (n=27, 3.07 (2.70-3.43)); p&lt;0.0001. Kaplan Meier survival estimates at 90 days (HMRS Low 91.0 ± 2.9%; HMRS Medium 91.7 ± 3.2 %; HMRS High 88.7 ± 6.1%), and at one year (HMRS Low 85.5 ± 3.8%; HMRS Medium 79.3 ± 5.5%; HMRS High 82.4 ± 8.4%) following LVAD implantation were not statistically different, p=0.43, Figure. HMRS discrimination to predict 90 day mortality by receiver characteristic curve analysis was poor, AUC=0.56. Conclusion: The HMRS successfully stratifies patients according to pre-operative clinical characteristics. In our HeartMate II LVAD population, the HMRS demonstrated poor discrimination for 90 day mortality. HMRS generalizability may be limited.
Abstract 9317: Impact of Trastuzumab-Induced Cardiotoxicity and Subsequent Trastuzumab Interruption on Breast Cancer Outcome
Authors: Anthony F Yu, Nandini U Yadav, Carlos R Manrique, Howard T Thaler, Clifford A Hudis, Chau T Dang, Richard M Steingart
Journal: Circulation (2013)

Background: Trastuzumab (T) improves disease free and overall survival among pts with HER2 (+) breast cancer (BCA); however this benefit is attenuated by the risk of trastuzumab-induced cardiotoxicity (TIC). Current guidelines recommend interruption of T for CHF or a significant reduction in LVEF, but the impact of this practice on BCA outcomes is unknown. Methods: All patients with HER2 (+) BCA receiving adjuvant T with chemotherapy in clinical practice at a single cancer center between January 2005 and June 2010 were studied. Tumor characteristics, cardiac risk factors, LVEF, BCA chemotherapy, and BCA outcomes were obtained from the medical record. The log rank test and Cox proportional model were used to evaluate the association between these variables and time to BCA recurrence. Results: Overall, 546 pts with HER2 (+) BCA treated with T were studied; 448 (82%) pts were treated with anthracyclines prior to T. Mean age was 51 yrs (range 26-81); mean follow-up was 4.4 yrs (range 0.6-7.6). T was interrupted for &gt; 1 cycle (&gt; 6 weeks) in 83 (15%) pts. TIC was the reason for interruption in 54 (9.9%) pts; 18 (3.3%) had symptoms of CHF with a decline in LVEF, while 36 (6.6%) had an asymptomatic decline in LVEF. Other reasons for interruption included non-cardiac adverse events (n=11), BCA progression (n=7), and pt request (n=7). Cumulative dose of T was lower among pts with interruption (median 76 vs. 106 mg/kg, p &lt; 0.0001). Early recurrence of BCA was associated with number of positive lymph nodes (p&lt;0.0001), negative progesterone receptor status (p=0.005), interruption of T &gt; 1 cycle for any cause (p=0.006), and interruption of T &gt; 1 cycle due to TIC (p=0.049, Table). Conclusions: TIC was the most common reason for interruption of T and was significantly associated with BCA recurrence. These results suggest that coordination of care between cardiologists and oncologists to limit T interruptions while effectively treating cardiotoxicity has the potential to improve outcomes in women with BCA.
Europeans and Americans turn to internet for health information
Authors: Lynn Eaton
Journal: BMJ (2002)

A third of European consumers have used the internet to get health information in the last year, according to a survey by the business analysts Datamonitor.

The company surveyed 4531 people in Europe and the United States and found that 32% of Europeans and 43% of Americans questioned had used the internet for health information.

But the consumers are more likely to use health websites sponsored by companies such as the BBC and Yahoo than websites connected directly with a pharmaceutical company, the government, or medical institutions.
Abstract 3644: Moderate Alcohol Consumption Is Associated With Improved Endothelial Function
Authors: Keiko Suzuki, Michell S Elkind, Bernadette Boden-Albala, Zhezhen Jin, Marco R Di Tullio, Ralph L Sacco, Shunichi Homma
Journal: Circulation (2007)

Background and Purpose: Moderate alcohol intake is protective against coronary artery disease. Endothelial dysfunction contributes to atherosclerosis and the pathogenesis of cardiovascular disease. Effects of alcohol consumption on endothelial function may be relevant to these cardiovascular outcomes, but very few human studies have examined the effect of alcohol consumption on endothelial function assessed by flow-mediated dilation (FMD) of the brachial artery. Methods: In the population-based Northern Manhattan Study (NOMAS), we performed a cross-sectional analysis of lifetime alcohol intake and brachial artery FMD during reactive hyperemia using high-resolution B-mode ultrasound images among 883 stroke free participants (mean age 66.7 years, women 56.6%, Hispanic 67.5%, black 17.5%, and white 14.9%). Results: The mean brachial FMD was 5.68% and the median was 5.52%. Reported lifetime alcohol consumption was as follows:147 (16.7%) non-drinkers (&lt;1drink/month), 616 (69.8%) &gt;1drink/mo to 2drinks/day, 59 (6.7%) &gt;2 to 5drinks/day, 60(6.8%) &gt;5drinks/day. Compared to non-drinkers, those who drank &gt;1 drink/mo to 2 drinks/day were more likely to have FMD above the median (5.5%) of FMD (unadjusted OR 1.7, 95% CI 1.2–2.5, p=0.004). In multivariate analysis, the relationship between moderate alcohol consumption and FMD remained significant after adjusting for multiple traditional cardiovascular risk factors, including age, body mass index, hypertension, diabetes and smoking (adjusted OR 1.5, 95%CI 1.1–2.2, p=0.02). No beneficial effect on FMD was seen for those who drank more than 2 drinks/day. Conclusion: Consumption of up to 2 alcoholic beverages per day independently was associated with improved FMD compared to nondrinkers in this multiethnic population compared to non-drinkers. The effect on FMD may represent an important mechanism in explaining the protective effect of alcohol intake on cardiovascular disease.
The influence of radiation therapy on survival among Medicaid-enrolled breast cancer patients treated with breast conserving surgery
Authors: K. L. Foley, F. Camacho, E. A. Levine, G. Kimmick, R. Balkrishnan, R. Anderson
Journal: Journal of Clinical Oncology (2006)

609 Background: A growing body of evidence indicates that breast cancer patients treated with breast conserving surgery (BCS) without radiotherapy (RT) have a greater risk of cancer recurrence and mortality compared to those receiving BCS plus RT. Most of the research to date has not included or accounted for women with lower socioeconomic status. Methods: Using cancer registry, Medicaid claims, and Social Security death index data, we evaluated receipt of RT and mean 6-year overall and cancer-specific survival among Medicaid-enrolled breast cancer patients treated with BCS (n=230). Logistic regression was used to assess predictors of RT. The Kaplan-Meier method was used to determine survival by RT status and a multivariate Cox proportional hazards regression model was used to evaluate the role of RT on overall and cause-specific survival while controlling for demographic, clinical, and comorbid factors. Results: 65% of women received RT. Overall, 82% of the sample survived the 5–6 year study period, with death rates of 16% compared to 51% among those who did and did not receive RT, respectively (p&lt;.001). Among the 24 individuals who died from cancer, 8 (33.3%) received radiation and 16 (66.7%) had not. After controlling for demographics, clinical factors, and comorbidity, use of RT was associated with a statistically significant decrease in all-cause mortality (hazard ratio = 0.42, 95% CI 0.21–0.85) and cancer-specific mortality (hazard ratio = 0.22, 95% CI −0.09–0.57). Conclusions: We found under-use of radiation following BCS in this Medicaid-enrolled population of breast cancer patients. Furthermore, omission of RT was associated with a greater than two-fold increased risk of death and almost a five-fold increase in cancer-specific death. Measures to improve RT use among poor women receiving BCS need to be implemented. No significant financial relationships to disclose.
Middle Age and Old Age.
Authors: Leonard Williams
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Do pharmaceutical claims accurately reflect oncology prescribing practice? Evidence from an Australian HER2+ early breast cancer cohort (HER2EBC).
Authors: Carole A. Harris, Robyn L. Ward, Benjamin Daniels, Sallie Pearson
Journal: Journal of Clinical Oncology (2013)

100 Background: Pharmaceutical claims are used increasingly to investigate the real-world use and impact of prescribed medicines. Claims databases are established for payment purposes, lack clinical data and only capture prescriptions for which insurers pay a contribution. We compare Pharmaceutical Benefits Scheme (PBS) dispensing claims of HER2EBC patients, with prescriptions written in oncology clinics to determine the accuracy of dispensing data to identify treatment protocols and estimate treatment cycles and durations of therapy. Methods: Our cohort comprised 110 female HER2EBC patients commencing treatment at 4 Sydney cancer centres between 2008 and 2011. Patients consented to medical chart audit and linkage to PBS claims. We constructed protocols from prescribing and dispensing records independently, based on the timing of trastuzumab and cytotoxic treatments; estimated the median number of treatment cycles and duration of therapy by protocol; and compared prescription and dispensing data. Results: Patients’ median age was 53 years (range 21.1-86.2). Based on prescribing data, 67 patients received anthracycline-containing protocols, 43 received taxane only protocols. ACTH and TCH accounted for 90% of all protocols. 75 patients (68.2%) were assigned the same protocols based on prescribing and claims data; 26 did not match as cyclophosphamide falls below the patient copayment for general PBS beneficiaries and is not captured in the claims data. Compared with prescription data, number of treatment cycles was underestimated in dispensing data (ACTH: median 30 vs 44; TCH 26 vs 29); trastuzumab-based treatment is administered weekly in ACTH but only dispensed 3-weekly. Durations of therapy differed by ≤5% in dispensing versus prescription data (ACTH 422 days vs 466; TCH 368 vs 367). Conclusions: PBS dispensing data is reliable for establishing treatment protocols in concessional beneficiaries and duration of therapy in all patients. Claims data underestimates treatment cycles as administration occurs more frequently than dispensing. These limitations must be considered when undertaking population-based studies using claims data in HER2EBC.
The Advancing Front of Medicine
Authors: George William Gray
Journal: JAMA (1942)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Instruments and Apparatus in Orthopaedic Surgery
Authors: E. J. Nangle
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal